News Pfizer suffers another hit to its GBT sickle cell portfolio Pfizer's $5.4 billion takeover of Global Blood Therapeutics three years ago is starting to look like a poor deal.
News After setback, Rhythm gets good news on Imcivree from FDA Rhythm Pharma has secured the first approval in the US for a drug to treat hypothalamic obesity.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.